Bayer’s stock dropped over 20% after halting a drug trial and facing a $1.56 billion Monsanto Roundup verdict. The company faces legal challenges with its products, including the failed anti-thrombotic drug asundexian. Despite setbacks, Bayer is confident in defending glyphosate’s safety, the active ingredient in Roundup, and plans to appeal recent rulings. The company navigates…